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 High-grade human chondrosarcomas have higher expression of translocase of the outer 
mitochondrial membrane complex subunit 20 (TOMM20) than low-grade tumors. 
 TOMM20 overexpression in chondrosarcoma cells increases markers of mitochondrial 
reprogramming, proliferation, and resistance to apoptosis. 
 TOMM20 overexpression in chondrosarcoma induces resistance to anticancer drugs.  
 TOMM20 overexpression in chondrosarcoma cells induces larger tumors in vivo.  
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Chondrosarcoma is the second most common primary bone malignancy, representing one fourth of all 
primary bone sarcomas. It is typically resistant to radiation and chemotherapy treatments. However, the 
molecular mechanisms that contribute to cancer aggressiveness in chondrosarcomas remain poorly 
characterized. Here, we studied the role of mitochondrial transporters in chondrosarcoma aggressiveness 
including chemotherapy resistance. Histological grade along with stage are the most important prognostic 
biomarkers in chondrosarcoma. We found that high-grade human chondrosarcoma tumors have higher 
expression of the mitochondrial protein, translocase of the outer mitochondrial membrane complex 
subunit 20 (TOMM20), compared to low-grade tumors. TOMM20 overexpression in human 
chondrosarcoma cells induces chondrosarcoma tumor growth in vivo. TOMM20 drives proliferation, 
resistance to apoptosis and chemotherapy resistance. Also, TOMM20 induces markers of epithelial to 
mesenchymal transition (EMT) and metabolic reprogramming in these mesenchymal tumors. In 
















Chondrosarcomas are malignant cartilaginous matrix-producing neoplasms [1] [2] [3]. They 
primarily affect adults and are the second most common type of bone malignancy after osteosarcoma [4]. 
Chondrosarcomas predominately arise in bone with endochondral ossification with the most common 
sites being the femur, pelvis, humerus, tibia and ribs [2]. Chondrosarcomas are classified based on 
morphology, whether they arise de novo (primary) or from a precursor benign lesion (secondary), or by 
location within the bone [1] [5] [6]. The majority of primary chondrosarcomas are classified as 
conventional and histological grading is the most important factor other than stage used to predict 
prognosis [7] [8] [9]. Chondrosarcomas are graded from 1 to 3 based on cellularity, nuclear size, nuclear 
atypia, mitotic activity, and matrix alterations [5]. Central atypical cartilaginous tumors 
(ACT)/chondrosarcoma grade 1 (CS1) neoplasms are low grade tumors, with a locally aggressive 
behavior. Tumors located in the appendicular skeleton are termed ACTs, whereas tumors located in the 
axial skeleton are termed CS1 [1]  [3]. Chondrosarcoma grades 2 and 3 (CS2 and CS3) are high grade 
chondrosarcomas with high local recurrence and metastatic potential with a five-year survival rate of 74-
99% for CS2 and 31-77% for CS3[1] [10]. Metastatic chondrosarcoma is incurable and leads to short 
overall survival [11]. Patients with low grade chondrosarcomas have less than 10% risk of metastasis, but 
metastatic risk increases to 50-70% in patients with high grade chondrosarcomas [2].  
The histological grade and tumor location determine treatment of chondrosarcomas. Surgical 
excision is currently the primary treatment approach for non-metastatic chondrosarcomas because 
chemotherapy agents and radiation are not effective [2] [12]. The type of surgery can range from 
curettage for atypical chondromatous tumors (ACT) or CS1 to  wide en-bloc excision for treatment of 
higher grade chondrosarcoma due to high risk of recurrence and metastasis [7]. However, en-bloc wide  
resection causes significant functional impairment [7]. Resistance to chemotherapy in chondrosarcoma 
was originally attributed to low proliferation rates and the hyaline cartilage and extracellular matrix, 
which restricts drug access to the cancerous cells [13] [14]. However, high grade lesions are also resistant 
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to chemotherapy despite lower amounts of matrix, increased vascularization, and increased proliferation 
[15] and high expression of anti-apoptotic proteins is now recognized as a resistance contributing factor 
[16].  
Mitochondrial metabolism is a driver of cancer aggressiveness in several human malignancies 
[17]. However, it is unknown if mitochondrial metabolism drives chondrosarcoma aggressiveness 
although isocitrate dehydrogenase (IDH) mutations, which modulate mitochondrial metabolism, are 
present in approximately 50% of chondrosarcomas and are the most common molecular event in this 
cancer subtype [1]. Also, glutaminolysis, which promotes mitochondrial metabolism, is a critical pathway 
in chondrosarcoma [17] [18]. Hence, we have studied the role of mitochondrial metabolism in 
chondrosarcoma aggressiveness.  
The molecular mechanisms and signaling pathways that are contributing to drug resistance in 
chondrosarcoma remain poorly defined. Although development of metastatic disease is the most feared 
complication of chondrosarcoma, local recurrence is also a major issue [2].  Many patients with high 
grade chondrosarcomas undergoing surgery with curative intent will subsequently have a local recurrence 
and surgery can induce profound disability [6].  Consequently, chondrosarcomas are associated with poor 
clinical outcomes that have not improved despite rapid advances in chemotherapy for almost all other 
cancer subtypes [15]. Most studies on chemotherapy and resistance in chondrosarcoma have involved the 
use of anthracyclines such as Doxorubicin, since this is the most commonly employed drug in the 
management of sarcomas [11] [19]. Thus we have studied the role of mitochondrial metabolism in driving 
anthracycline resistance in chondrosarcoma. 
 Altered metabolism is a hallmark of cancer [20] and mitochondrial activity is increased in a 
subset of human cancers [17] [21] [22]. Most mitochondrial proteins are encoded by nuclear genes and 
are synthesized by cytosolic ribosomes with mitochondrial targeting signal sequences [23]. Translocase of 
the outer mitochondrial membrane complex subunit 20 (TOMM20) has been shown to be an important 
subunit of the translocase of the outer mitochondrial membrane complex that is responsible for 
recognizing and translocating mitochondrial proteins from the cytosol into the mitochondria [24] [25]. 
Journal Pre-proof
The components of the translocase of the outer mitochondrial membrane complex have been shown to 
aggregate into clusters at the membrane and the density of these clusters are tightly correlated with 
activity of the mitochondria [23]. The density of the TOMM20 clusters is higher in mitochondria with 
higher mitochondrial membrane potential [23]. Therefore, cells with greater mitochondrial mass and 
higher mitochondrial activity have more TOMM20 expression [23]. TOMM20 has previously been 
shown to be highly expressed in human epithelial and lymphoid cancers and is a prognostic biomarker 
[26] [27] [28] [29] [30].  
In this study we set out to determine mechanisms of chemotherapy resistance in chondrosarcoma. 
Here, we determined that high grade human chondrosarcomas have high expression of TOMM20, TP53 
Induced Glycolysis and Apoptosis Regulator (TIGAR), and Monocarboxylate Transporter 1 (MCT1) 
suggesting that aggressive chondrosarcomas have high mitochondrial oxidative phosphorylation 
(OXPHOS) metabolism. TOMM20 over-expression in chondrosarcoma cells promotes cancer 
aggressiveness by increasing tumor growth, invasiveness, proliferation, resistance to apoptosis, and 




Chemical Compounds. Drug compounds were purchased from Sigma: Palbociclib (PZ0383, Millipore 
Sigma, Burlington, MA), Doxorubicin (D1515, Sigma Aldrich, St. Louis MO), Gemcitabine (G6423, 
Sigma Aldrich), Antimycin A (A8674, Sigma Aldrich), and Rotenone (45656, Sigma Aldrich). 
 
Human Studies. This study was approved by the institutional review board (IRB) at Thomas Jefferson 
University. Samples from low grade (ACT/CS1), and high grade (CS2 and CS3) chondrosarcomas were 
obtained from archived paraffin embedded tissue blocks for TOMM20, MCT1 and TIGAR histological 
analyses. The samples were scored by a bone and soft tissue tumor pathologist (W.J.) for each antibody. 
Percentage of tumor cells with positive staining was assessed.  Intensity of staining within tumor cells 
was also assessed using a semiquantitative system with 0 having no staining, 1+ weak staining, 2+ 
moderate staining and 3+ high staining.  
The relationship between MCT1 intensity and histological grade was analyzed by fitting a continuation 
ratio for ordinal responses with logit-link model using R [31]  package VGAM [32].  The relationship 
between TOMM20 or TIGAR intensity and histological grade was analyzed by fitting a Firth's bias-
reduced logistic model using R package logistf [33] because of a lack of moderate and high intensity in 
the low-grade group. The relationship between percentage positive for TOMM20, MCT1 and TIGAR and 
intensity and histological grade was analyzed by fitting a multivariable linear mixed effects model with 
random effects of sample using R package nlme [34].     
 
Immunohistochemistry. Tumor samples of ACT/CS1, which are low grade chondrosarcomas (N=29) 
and CS2 and CS3, which are high grade chondrosarcomas (N=10) were stained by immunohistochemistry 
(IHC). Samples were stained with antibodies to TOMM20 (F-10) (1:5000; sc-17764, Santa Cruz 
Biotechnology, Dallas, TX), MCT1 (SLC16A1) 19-mer peptide (1:1000; YenZym Antibodies, South San 
Francisco, CA) and TIGAR (1:750; ab62533, Abcam, Cambridge, MA). Tissue sections were 
deparaffinized, rehydrated and antigen retrieval was performed on the Ventana Discovery ULTRA 
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staining platform using Discovery CCI (Ventana #950-500, Roche Diagnostics, Indianapolis, IN) for a 
total application time of 64 minutes. Primary immunostaining was performed for 45 min followed by 
secondary immunostaining using a Horseradish Peroxidase (HRP) multimer cocktail (Ventana #760-500) 
and immune complexes were visualized using the ultraView Universal DAB (diaminobenzidine 
tetrahydrochloride) Detection Kit (Ventana #760-500). Slides were then washed with a Tris based 
reaction buffer (Ventana #950-300) and stained with Hematoxylin II (Ventana #790-2208) for 8 minutes. 
For mouse tumor staining, a manual 3-step HRP method was used. Four micron tumor xenograft paraffin 
sections were deparaffinized and rehydrated. Antigen retrieval was performed in 10mM citrate buffer pH 
6.0 for 10 minutes with a pressure cooker followed by blocking for endogenous peroxidase with 3% H202 
for 15 minutes. Blocking was also performed for endogenous biotin with an avidin-biotin blocking kit 
(Biocare Medical, Pacheco, CA). Samples were then incubated with 10% goat serum overnight at 4C 
and the next day with anti-phospho-RB (1:500; #8516, Cell Signaling, Danvers, MA) for one hour at 
room temperature. After washing in PBS, the sections were incubated with a biotinylated goat-anti-rabbit 
IgG antibody followed by an avidin-biotinylated horseradish peroxidase complex (PK-6100, Vector 
Laboratories, Burlingame, CA). Immunoreactivity was determined using liquid DAB substrate 
chromogen (Agilent #K346811-2, Santa Clara, CA) and samples were counterstained with hematoxylin.  
 
 
Phospho-retinoblastoma (phospho-RB) Quantification. Phospho-RB staining in L2975 control and 
TOMM20 xenograft sections were quantified using Aperio software (Aperio, Nussloch, Germany). 
Briefly, digital images were captured with Leica and Aperio scanners under 3203 magnification with an 
average scan time of 120 seconds (compression quality, 70). A nuclear algorithm was used to identify 
phospho-RB positive nuclei and generate percentage positive nuclei in each of 9-11 areas per sample 
encompassing the majority of the viable tumor area for a total of 19 areas in the EV control and group and 




Cell culture. The human chondrosarcoma cell line SW1353 was obtained from American TType Culture 
Collection (ATCC) and L2975 and CH2879 were a kind gift from Professor Judith Bovee at the Leiden 
University Medical Center, The Netherlands and Professor Antonio Llombart Universidad de Valencia, 
Spain. Cells were cultured in media containing 4.5 g/L glucose, 1mM pyruvate, 10% FBS, 100 units/mL 
penicillin, and 100 units/mL streptomycin at 37C, 5% CO2. RPMI cell culture media was used as the 
base medium for all cell lines.  
 
Overexpression of TOMM20. HA-TOMM20 (EX-G0283-Lv120) and HA-control (EX-NEG-Lv120) 
lentiviral vectors were purchased from GeneCopoeia (Rockville, MD). Lentiviruses were prepared 
according to the manufacturer’s protocol. Virus containing media was centrifuged, filtered with a 0.45 
micron PES low protein filter, divided into 1 mL aliquots and stored at -80C. Chondrosarcoma cells 
were seeded in 6-well culture dishes at 250,000 cells per well in growth media. At 24 hours post-seeding, 
the media was removed and replaced with 1mL of media containing 5% FBS, 5ug/uL polybrene and 1 mL 
of virus containing media. Virus containing media was removed 24 hours post-infection and replaced 
with growth media. The cells were selected with puromycin (2ug/mL) for 3 days after infection.  
 
Proteomic Analysis. 2D DIGE (two-dimensional difference gel electrophoresis) and mass spectrometry 
protein identification were run by Applied Biomics (Hayward, CA) as previously described [35]. Briefly, 
image scans were performed immediately after SDS-PAGE using Typhoon TRIO. All of the images were 
analyzed using Image QuantTL software and subjected to in-gel and cross-gel analysis and protein 
differential expression was determined using DeCyder software. Image analysis spots were selected and 
subjected to in-gel trypsin digestion, peptide extraction, desalting, and MALDI-TOF/TOF (Applied 
Biomics, Hayward, CA) analysis to determine protein identity. All samples were prepared by washing 
cells 3X with cold PBS. Cells were scraped into 1.5mL micocentrifuge tubes and centrifuged at 13,000X 
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g at 4C for 15 minutes to generate a cell pellet. All samples were stored at -80C until shipment. Proteins 
with 1.5 or greater fold change were considered to be upregulated in TOMM20 overexpressing cells 
compared to control.  
 
Immunoblot Analysis. Cell protein lysates were obtained by extraction with lysis buffer containing 
10mM Tris, pH 7.5, 150mM NaCl, 1% Triton X-100, and 60mM n-ocytlglucoside containing protease 
and phosphatase inhibitors. Extracts were rotated at 4C for 40 minutes and centrifuged at 13,000X g at 
4C for 15 minutes to remove the pellet. The protein concentration of all samples were determined by 
BCA reagent. Samples were separated by SDS PAGE and transferred to nitrocellulose membrane. 
Primary antibodies and dilutions are described in Table 1. Protein expression levels were determined by 
calculating densitometry and normalized to loading control.  
 
Apoptosis. Apoptosis in culture was quantified by flow cytometry using PI and Annexin-V-APC. Cells 
were harvested and centrifuged and resuspended in Annexin-V binding buffer containing the Annexin V-
APC conjugate (BDB550474, BD Biosciences, San Jose, CA) (8uL/mL) and DAPI (0.2-0.5ug/mL). 
Apoptotic cells (early, late, or dead) were identified using the BD LSR Fortessa cell analyzer. Statistical 
analysis was examined in GraphPad Prism using Student’s t-test. Values of p<0.05 were considered 
statistically significant.  
 
Proliferation. For DNA content and proliferation analyses, cells were incubated with 10uM EDU for 1 
hour. Click-iT EdU Flow Cytometry Assay kit (C10418, Life Technologies) and FxCycle™ Far 
Red Stain (F10348, Life Technologies, Carlsbad, CA) for cell cycle analysis was performed 
according to the standard protocol. Data was analyzed by Flowjo software. Statistical analysis was 
examined in GraphPad Prism using Student’s t test. Values of p<0.05 were considered significant.  
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Oxygen Consumption Rate Assessment. A Seahorse Bioscience XF24 Extracellular Flux Analyzer was 
used. CH2879 and SW1353 cells were preseeded in the XF24 24- well plate with 100uL of  RPMI growth 
media containing 10% fetal bovine serum, 100 units/mL penicillin, 100 units/mL streptomycin in a 37C, 
5% CO2 incubator for one hour to allow for cell attachment. After one hour, an additional 200uL of 
growth media was added for a total volume of 300uL per well. On the second day, cells were incubated in 
non-buffered media containing 5mM glucose in a CO2 free incubator for one hour. Oxygen consumption 
measurements were obtained under basal conditions, after injection of 10mM lactate, and after injection 
of 0.5µM antimycin A and 0.5µM rotenone. Statistical analysis was performed using Student’s t-test. 
Values of p<0.05 were considered statistically significant. For CH2879 N=12 and for SW1353 N=6. 
 
Animal Studies. To evaluate the in vivo effects of TOMM20 overexpression on chondrosarcoma tumor 
growth, cells were injected into the flank of athymic NCr nude mice (Nu/Nu; Charles River at 6 weeks of 
age). All animals were maintained in a pathogen-free environment/barrier facility at the Sidney Kimmel 
Cancer Center at Thomas Jefferson University. The Institutional Animal Care and Use Committee 
(IACUC) approved all animal protocols and all experiments were performed in accordance with the 
National Institute of Health guidelines. L2975 cells were injected into the flank of male nude mice and 
CH2879 cells were injected into the flank of female nude mice following isoflurane anesthesia. For these 
studies, 2 million cancer cells were resuspended in 100µL of sterile PBS before injection. For each mouse 
experiment there were 5 mice injected bilaterally per experimental group for a total of 10 per group. Mice 
were sacrificed 4-12 weeks post-injection via CO2 inhalation and tumors were excised. Tumor volume 
was calculated using the formula V=X^2*Y/2 where V is the tumor volume, X is the length of the short 
axis and the Y is the length of the long axis measured using electronic calipers and tumor weight was 
measured in grams.  Statistical analysis was performed using the Mann Whitney U Test in GraphPad 




TOMM20, MCT1 and TIGAR expression in human chondrosarcoma  
A cohort of 10 low grade chondrosarcomas (CS1) and 29 high grade chondrosarcomas (CS2 and CS3) 
were stained with antibodies to TOMM20, TIGAR, and MCT1 by immunohistochemistry (IHC) (Figure 
1A). The samples were scored by a bone and soft tissue tumor pathologist for percentage of positive 
tumor cells and for staining intensity. Positive cells were defined as those that had at least weak 
expression. Also, the samples were scored for intensity semi-quantitatively using a 1+, 2+ and 3+ scoring 
system, where 1+ corresponded to weak expression, 2+ corresponded to moderate expression and 3+ 
corresponded to high expression.  
The percentage of tumor cells that were positive for TOMM20 and TIGAR was higher in high grade 
compared to low grade chondrosarcomas (Figure 1A) (p<0.05). There was a trend towards a higher 
percentage of tumor cells that were positive for MCT1 in high grade chondrosarcomas compared to low 
grade chondrosarcomas but this was not statistically significant (Figure 1A) (p<0.23). The intensity of 
TOMM20, TIGAR, and MCT1 on tumor cells was higher in high grade chondrosarcomas compared to 
low grade chondrosarcomas (Figure 1B) (p<0.05).  The percentage of tumor cells that were positive for 
TOMM20, TIGAR, and MCT1 positively correlated with TOMM20, TIGAR, and MCT1intensity 
respectively (Figure 1C) (p<0.05).  These data demonstrate that high grade chondrosarcomas have higher 
TOMM20 and TIGAR expression, which are markers of mitochondrial mass.   
TOMM20 overexpression increases markers of cancer aggressiveness  
To evaluate the effects of TOMM20 overexpression on chondrosarcoma aggressiveness, we 
overexpressed TOMM20 in the chondrosarcoma cells lines CH2879, L2975, and SW1353 (Figure 2A). 
Proteomic analysis was performed to determine the effect of TOMM20 overexpression on the 
chondrosarcoma cells and assess changes in protein levels and cellular processes in an unbiased fashion. 
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The results of the proteomic analysis are summarized in Table 2. String DB was used with modifications 
to generate a network based on the proteins that increased with TOMM20 overexpression and on known 
and predicted protein-protein interactions (Figure 2B). The proteins and pathways that were found to be 
upregulated with TOMM20 overexpression by proteomic analysis were used to identify which pathways 
should be further studied. The most upregulated proteins with at least 1.5-fold increase in expression 
between the control and TOMM20 overexpressing cells were selected. We studied invasion, proliferation, 
apoptosis, mitochondrial metabolism, and markers of cancer aggressiveness by evaluating the expression 
of classical makers in the empty vector control (EV) and TOMM20 overexpressing cells. To study cancer 
aggressiveness and invasiveness, we analyzed expression of N-cadherin and phosphorylated STAT3, 
which are markers of an epithelial to mesenchymal transition (EMT) by immunoblot. TOMM20 
overexpression increases N-cadherin and phospho-STAT3 compared to the EV control (Figure 2C). We 
evaluated the expression of cyclin D1 and c-MYC as markers of cell cycle progression and proliferation 
by immunoblot. TOMM20 overexpression increases cyclin D1 and c-MYC expression compared the EV 
control (Figure 2D-E). To study resistance to apoptosis with TOMM20 overexpression we evaluated the 
expression of the anti-apoptotic protein BCL2 in the EV control and TOMM20 overexpressing cells by 
immunoblot. We found that TOMM20 overexpression increases BCL2 expression compared to EV 
control (Figure 2F). TOMM20 overexpression increased the percentage of cells in S phase 1.3-fold 
compared to EV control cells (Figure 2G).  Taken together, these data demonstrate that TOMM20 
overexpression in chondrosarcoma cells may increase markers of aggressiveness by increasing the 
expression of proteins involved in invasion and metastasis, proliferation, and resistance to apoptosis 
(Figure 6F). 
TOMM20 overexpression increases mitochondrial metabolism 
To assess the effect of TOMM20 overexpression on mitochondrial metabolism we studied the expression 
of TIGAR and MCT1 in EV control and TOMM20 overexpressing cells. The expression of TIGAR and 
MCT1 increases in TOMM20 overexpressing cells (Figure 3A-B). To further characterize the effects of 
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TOMM20 on mitochondrial metabolism and OXPHOS, we studied oxygen consumption rates (OCR) in 
EV control and TOMM20 overexpressing chondrosarcoma cells. OCR was measured under basal 
conditions with media containing 5mM glucose, after exposure to 10mM lactate, and after treatment with 
0.5µM Antimycin A and 0.5µM Rotenone. Antimycin A, a complex III inhibitor, and Rotenone, a 
complex I inhibitor, were used in combination to inhibit the mitochondrial electron transport chain in 
order to determine the contribution of non-mitochondrial sources to OCR [36] [37]. CH2879 TOMM20 
overexpressing cells have 1.5-fold greater OCR than EV control cells at baseline and 1.4-fold greater 
OCR after lactate exposure (Figure 3C) (p<0.05). SW1353 TOMM20 overexpressing cells have 1.3-fold 
greater OCR than EV control cells at baseline and 1.4-fold greater OCR after lactate exposure (Figure 
3D) (p<0.05). Treatment of both CH2879 and SW1353 cells with Antimycin A and Rotenone caused the 
expected reduction in oxygen consumption in both EV control and TOMM20 overexpressing cells. After 
subtraction of the non-mitochondrial oxygen consumption the increased OCR in TOMM20 
overexpressing cells was maintained both at baseline and after lactate exposure. These data demonstrate 
that TOMM20 overexpression increases mitochondrial OCR and therefore increases mitochondrial 
OXPHOS metabolism in CH2879 and SW1353 cells. TOMM20 overexpressing cells also have increased 
OCR after lactate exposure suggesting that chondrosarcoma cells can utilize and catabolize lactate via 
mitochondrial OXPHOS metabolism. Taken together these data suggest that TOMM20 overexpression 
promotes mitochondrial metabolism (Figure 6F).  
TOMM20 overexpression induces cancer chemotherapy resistance  
Since TOMM20 overexpression increased markers of cancer aggressiveness including proliferation and 
resistance to apoptosis, we wanted to determine if TOMM20 overexpression can lead to resistance to 
anticancer drugs that target proliferating cells that have been studied in the context of chondrosarcoma 
such as Gemcitabine, Doxorubicin and Palbociclib. Gemcitabine and Doxorubicin are commonly used 
agents to treat sarcomas [11] [19] and recently the cyclin dependent kinase 4/6 inhibitor Palbociclib that 
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targets proliferating cells has shown promise in chondrosarcoma preclinical models [38]. 
Chondrosarcoma cells were treated with Palbociclib and Gemcitabine alone or in combination, to 
determine the effects of these drugs on the proliferation of chondrosarcoma cells. Treatment with 
Palbociclib led to a 1.1-fold reduction, Gemcitabine led to a 3.2-fold reduction, and the combination of 
Palbociclib and Gemcitabine led to a 5.3-fold reduction in the percentage of cells in G2-M and S phase 
(Figure 4A) (p<0.05). We assessed the amount of cell death induced by the treatment of Palbociclib, 
Doxorubicin, and the combination. Treatment with Palbociclib alone induced a 1.2-fold increase, 
Doxorubicin induced a 2.6-fold increase, and the combination of Palbociclib and Doxorubicin induced a 
5.1-fold increase in the percentage of apoptotic cells (Figure 4B) (p<0.05). Since treatment with these 
compounds led to reduced proliferation and increased cell death in chondrosarcoma cells, we wanted to 
determine the effects of TOMM20 overexpression on therapy efficacy in chondrosarcoma cells. EV 
control and TOMM20 overexpressing cells were exposed to Gemcitabine and then evaluated for 
apoptosis. The TOMM20 overexpressing cells had a 1.6-fold reduction in cell death compared to the EV 
control (Figure 4C) (p<0.05). Due to lack of activity of single chemotherapeutic agents in 
chondrosarcoma we investigated combination treatments in the context of TOMM20 overexpression. EV 
control and TOMM20 overexpressing cells were treated with Gemcitabine, Palbociclib, and the 
combination and proliferation rates were evaluated. At baseline, TOMM20 overexpressing cells had a 
1.2-fold increase in the percentage of cells in G2-M and S phase compared to EV control cells (Figure 
4D) (p<0.05). Treatment with Gemcitabine, Palbociclib, or the combination induced an 11-fold, 6-fold, or 
12-fold reduction in proliferation in EV control cells compared to TOMM20 overexpressing cells (Figure 
4D). EV control and TOMM20 cells were treated with Doxorubicin, Palbociclib, and the combination of 
Doxorubicin and Palbociclib and evaluated for proliferation rates as measured by the percentage of cells 
in G2-M, and S phase. Treatment with Doxorubicin, Palbociclib, or the combination induced a 4.2-fold, 
7-fold, or 13-fold reduction in proliferation of EV control cells compared to TOMM20 overexpressing 
cells (Figure 4E) (p<0.05). TOMM20 overexpressing and EV control cells were also evaluated for 
apoptosis levels after treatment with Gemcitabine, Palbociclib and the combination. Under control 
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conditions, TOMM20 overexpressing cells had a 1.4-fold reduction in apoptosis levels (Figure 4F) 
(p<0.05). After treatment with Gemcitabine, Palbociclib and the combination, TOMM20 cells had a 1.4, 
1.3 and 1.6-fold reduction respectively in apoptosis rates compared to EV control cells (Figure 4F) 
(p<0.05). Taken together these data demonstrate that TOMM20 overexpression in chondrosarcoma 
induces resistance to commonly used chemotherapies, which is consistent with an aggressive phenotype 
(Figure 6F).  
TOMM20 overexpression induces larger tumors 
Since TOMM20 overexpression induces a more aggressive cancer phenotype in chondrosarcoma cells, 
we wanted to determine if TOMM20 overexpression had an effect on tumor size in vivo. L2975 tumors 
with T0MM20 overexpression had 86.0-fold greater volume and 31.0-fold greater weight than EV control 
tumors (Figure 5A- B) (p<0.05). L2975 chondrosarcoma cells overexpressing TOMM20 had greater 
engraftment rates with 80 percent successful engraftment compared to the EV control cells that had only 
20 percent successful engraftment (Figure 5C) (p<0.05). TOMM20 overexpressing L2975 tumors had 
1.9-fold higher expression of phosphorylated Retinoblastoma (p-Rb) than EV control tumors (Figure 5D) 
(p<0.05). Tumor growth was also evaluated in CH2879 TOMM20 overexpressing and EV control cells. 
CH2879 TOMM20 overexpressing cells had a 5.2-fold greater volume and 2.8-fold greater weight than 
EV control tumors (Figure 5E-F) (p<0.05). Taken together, TOMM20 overexpression in chondrosarcoma 
cells promotes tumor growth.  
TOMM20 overexpression induces expression of markers of mitochondrial reprogramming in 
tumors.  
Tumors that were generated by injection into mice of cancer cells with overexpression of translocase of 
the outer mitochondrial membrane subunit 20 (TOMM20) or EV control tumors were analyzed for 
protein expression by immunoblot. Here we studied in vivo, the expression of several proteins associated 
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with mitochondrial metabolic function by evaluating the expression of monocarboylate transporter 1 
(MCT1), TP53-inducible glycolysis and apoptosis regulator (TIGAR) and mitoNEET. TOMM20 
increased 1.8-fold in tumors overexpressing TOMM20 compared to EV control (Figure 6A) (p<0.05). 
The monocarboxylate transporters (MCTs) are a family of proton-linked membrane transporters that are 
responsible for the movement of single-carboxylate molecules such as lactate in and out of cells [39]. 
MCT1 has been found to be upregulated in cancer cells that have increased lactate uptake and oxidative 
phosphorylation (OXPHOS) metabolism. MCT1 increased 1.9-fold in TOMM20 overexpressing tumors 
compared to EV control (Figure 6B) (p<0.05). TIGAR has been described to be expressed in several solid 
tumor types and has been shown to induce OXPHOS in cancer cells [40]. TIGAR increased 1.3-fold in 
TOMM20 overexpressing tumors compared to EV control (Figure 6C) (p<0.05). To evaluate 
mitochondrial mass and energy regulation in tumors overexpressing TOMM20 we also studied 
mitoNEET expression. MitoNEET is an outer mitochondrial membrane protein containing an iron-sulfur 
cluster, which regulates oxidative capacity of the mitochondria [41]. MitoNEET expression increased 1.6-
fold in tumors generated by TOMM20 overexpression compared to EV control (Figure 6D) (p<0.05).  We 
also studied expression of BCL2 as a marker of mitochondrial anti-apoptotic function in chondrosarcoma 
tumors in mice. BCL2 expression increased 1.2-fold in tumors generated with TOMM20 overexpression 
compared to EV control (Figure 6E) (p<0.05). Therefore, MCT1, TIGAR, mitoNEET and BCL2 
expression are increased upon overexpression of TOMM20.  
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Discussion 
Chondrosarcomas are a clinically heterogeneous group of primary bone cancers that arise in bone with 
endochondral ossification [42]. Conventional chondrosarcomas are typically resistant to cytotoxic 
chemotherapy and therefore there are no effective therapies for patients with metastatic or inoperable 
chondrosarcomas [11]. It is important to study the biological events that drive chondrosarcoma 
aggressiveness to support the investigation of novel treatments for this complex disease.  
Little is known about the metabolism of chondrocytes and the metabolism of chondrosarcomas. However, 
studies have suggested that mitochondrial metabolism may be important since it has been shown that 
isocitrate dehydrogenase mutations are common in chondrosarcoma and occur in approximately 50% of 
cases and there have also been reports of  high glutaminolysis activity, high NAD flux, activation of the 
mTOR pathway as well as alterations in  lipid metabolism in chondrosarcoma [43] [44] [45] [18] [46] 
[47]. However, other studies in chondrosarcomas based on expression analysis have suggested that 
glycolysis might be increased or OXPHOS reduced [48] [49]. Here, we studied mitochondrial protein 
import as a potential mechanism of chondrosarcoma aggressiveness and therapy resistance. We studied 
the expression of the translocase of the outer mitochondrial membrane subunit 20 (TOMM20) in human 
chondrosarcomas.  High TOMM20 expression has been described in human epithelial and lymphoid 
cancers and is associated with poor outcomes [26] [27] [28] [29] [30]. We describe for the first time that 
TOMM20 is highly expressed in high grade compared to low grade human chondrosarcomas, suggesting 
that aggressive chondrosarcomas have increased mitochondrial metabolism. Future studies will be needed 
to further characterize the expression in normal human cartilage due to lack of access to these tissues for 
this study. 
TOMM20 overexpressing chondrosarcoma cells were used to determine the effects of mitochondrial 
metabolism on cancer aggressiveness. From an unbiased proteomics analysis, we found that TOMM20 
overexpression led to changes in protein expression associated with increased cancer aggressiveness 
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including invasiveness, proliferation, resistance to cell death, and mitochondrial metabolism. Pathways 
and processes revealed by the proteomic analysis were then studied in TOMM20 overexpressing 
chondrosarcoma cell lines. N-cadherin and phosphorylated STAT3 both of which are involved in an 
epithelial to mesenchymal transition, invasion, and metastasis are increased in cells overexpressing 
TOMM20. Also, TOMM20 overexpressing cells have higher proliferation rates with a higher proportion 
of cells in S phase and increased expression of cyclin D1 and c-MYC. Lactate uptake and mitochondrial 
metabolism is upregulated by c-MYC, MCT1 and TIGAR[17] [40] [50] [51].  We demonstrate here that 
TOMM20 drives expression of c-MYC, MCT1 and TIGAR. Since MCT1 can be localized in the plasma 
membrane and in the mitochondrial membrane future studies will be required to further elucidate the 
localization of MCT1 and lactate dehydrogenase B (LDH-B) to differentiate between lactate uptake into 
the cell or into the mitochondria [52]. Resistance to apoptosis is another common feature of aggressive 
cancer including chondrosarcoma [53] and here we observed that TOMM20 overexpression leads to 
upregulation of the anti-apoptotic protein BCL2. Our data suggests that TOMM20 overexpression induces 
a more aggressive phenotype in chondrosarcoma.  
To assess the effect of TOMM20 overexpression on mitochondrial metabolism, OCR was measured 
under baseline conditions with 5mM glucose, after exposure to 10mM lactate, and after addition of 
0.5µM Antimycin A and 0.5µM Rotenone. We demonstrate that TOMM20 overexpression drives 
increased oxygen consumption rates and therefore mitochondrial metabolism. This increase in OCR is 
maintained after subtraction of non-mitochondrial oxygen consumption, which was determined by 
treatment with the mitochondrial electron transport chain inhibitors Antimycin A and Rotenone. 
TOMM20 overexpressing cells also have increased OCR after lactate exposure suggesting that 
chondrosarcoma cells can utilize and catabolize lactate via mitochondrial OXPHOS metabolism. Future 
studies will need to be performed to determine if in addition to glucose and lactate other substrates are 
utilized for mitochondrial oxygen consumption more efficiently by TOMM20 overexpressing cells. Here 
we have found a relationship between the expression of TOMM20 and oxygen consumption rates, but 
Journal Pre-proof
futures studies are needed to further determine the exact link between the expression of TOMM20 and 
OCR.  
Chondrosarcoma is resistant to chemotherapy agents although Gemcitabine, Palbociclib or anthracyclines 
in combination with other agents appear promising [2] [11] [13] [19] [38] [54] [55]. TOMM20 
overexpression in chondrosarcoma cells induced resistance to commonly used cell cycle specific 
chemotherapy agents. Treatment with Palbociclib, Doxorubicin, and Gemcitabine alone or in combination 
in parental chondrosarcoma cells led to a reduction in proliferation rates and increased apoptosis, 
demonstrating activity. However, we found that TOMM20 overexpressing chondrosarcoma cells were 
resistant to treatment of these agents alone or in combination. Therefore, we have discovered that 
TOMM20 in chondrosarcoma induces resistance to cell cycle specific chemotherapy agents. Future 
studies will need to determine if this is due to upregulation of BCL2 and/or other antiapoptotic proteins.  
TOMM20 overexpression in cells provides a growth advantage in vivo. Chondrosarcoma cells 
overexpressing TOMM20 injected into mice generate larger tumors than injection of control cells. 
TOMM20 overexpressing L2975 cells also had more significant successful engraftment in mice than 
control cells. Tumors generated from L2975 cells overexpressing TOMM20, also had increased phospho-
Rb levels compared to the control tumors, demonstrating that TOMM20 tumors had higher rates of 
proliferation in vivo similar to that observed with TOMM20 overexpressing cells in vitro. 
In sum, this study demonstrates that TOMM20 overexpression leads to chondrosarcoma aggressiveness. 
We found that TOMM20 is expressed in human chondrosarcomas and when overexpressed in 
chondrosarcoma cells, increases expression of markers of cancer aggressiveness and promotes tumor 
growth. These data suggest that TOMM20 expression promotes tumor growth by promoting 
mitochondrial metabolism, increasing proliferation, and inducing markers of an epithelial to 
mesenchymal transition (EMT), which are consistent with other studies showing an association between 
TOMM20 expression and outcomes in human cancers [26] [27] [28] [29] [30]. These changes in 
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chondrosarcoma cells induced by TOMM20 overexpression also induce resistance to cell cycle specific 
chemotherapy agents. Therefore, these data suggest that the expression of TOMM20 in chondrosarcomas 
could be a key driver of drug resistance and a potential mechanism of resistance to cell cycle specific 
chemotherapy agents. This is consistent with previous work demonstrating that the antiapoptotic protein 
BCL2 drives chemotherapy resistance [16]. Future studies will need to determine if agents targeting 





Figure 1. TOMM20, MCT1 and TIGAR expression in human chondrosarcomas. A, Representative 
images of immunohistochemistry for TOMM20, TIGAR, and MCT1 with CS1 and CS3 samples are 
shown. B, Percent positive cells and overall staining intensity were measured. Note that the percentage of 
tumor cells positive for TOMM20 and TIGAR is higher in high-grade chondrosarcoma (p<0.05) but not 
for MCT1 (p<0.23). C, Staining intensity for TOMM20, TIGAR, and MCT1 positively correlates with 
the percentage of tumor cells that are positive for TOMM20, TIGAR, and MCT1 respectively and higher 
grade tumors have higher staining intensity (p<0.05). *p<0.05 
 
Figure 2. Effect of TOMM20 on markers of cancer aggressiveness. A, HA-TOMM20 immunoblot in 
CH2879, L2975, and SW1353 cells with TOMM20 overexpression compared to EV control. In CH2879 
cells the two bands represent HA variants. B, The proteins identified from the proteomic analysis was 
subjected to String v11.0 analysis to identify functional interactions between the deregulated proteins. 
Each node represents a protein and each edge represents an interaction. C, Phospho-STAT3 tyr705 and 
N-cadherin immunoblot of EV control and TOMM20 overexpressing L2975 and SW1353 cells. D, Cyclin 
D1 immunoblot of EV control and TOMM20 overexpressing L2975 and CH2879 cells. E, C-MYC 
immunoblot of EV control and TOMM20 L2975 and CH2879 overexpressing cells. F, BCL2 immunoblot 
of EV control and TOMM20 overexpressing L2975 and SW1353 cells. G, Proliferation rates were 
measured with EdU incorporation and the cell cycle was assessed in carcinoma cells. DNA synthesis was 
measured with EdU-PE incorporation and ploidy was assessed with FxCycle™ Far Red Stain (N=3). 
All immunoblots are representative examples,*p<0.05. 
 
Figure 3. TOMM20 overexpression promotes mitochondrial metabolism. A, TIGAR immunoblot of 
EV control and TOMM20 overexpressing CH2879 and SW1353 cells. B, MCT1 immunoblot of EV 
control and TOMM20 overexpressing L2975 and CH2879 cells. C, Oxygen consumption was measured 
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in EV control (blue) and TOMM20 overexpressing (red) CH2879 cells. Oxygen consumption was 
measured under baseline conditions with 5mM glucose, after injection of 10mM lactate, and after 
injection of 0.5µM Antimycin A and Rotenone. OCR values were normalized to protein concentration 
(N=12). D, Oxygen consumption was measured in EV control (blue) and TOMM20 overexpressing (red) 
SW1353 cells. Oxygen consumption was measured under baseline conditions with 5mM glucose, after 
injection of 10mM lactate, and after injection of 0.5µM Antimycin A and Rotenone. OCR values were 
normalized to protein concentration (N=6). *p<0.05 
 
Figure 4. Effect of TOMM20 overexpression on therapy resistance. A Proliferation rates 
were measured with EdU incorporation and the cell cycle was assessed in carcinoma cells. DNA 
synthesis was measured with EdU-PE incorporation and ploidy was assessed with FxCycle™ Far 
Red Stain in L2975 chondrosarcoma cells after treatment with 20nM Palbociclib, 50nM 
Gemcitabine, and the combination of 20nM Palbociclib and 50nM Gemcitabine. B, Apoptosis 
levels were measured with Annexin-V (AnnV) and DAPI staining after treatment with 2µM 
Palbociclib, 2µM Doxorubicin, and the combination of 2µM Palbociclib and 2µM Doxorubicin. 
The percentage of apoptotic or dead L2975 cells (Annv-V- positive and/or DAPI positive) is 
shown. C, Apoptosis levels were measured in EV control and TOMM20 overexpressing L2975 
cells after treatment with 5µM Gemcitabine (Gemzar). D, Proliferation rates were measured with 
EdU incorporation and the cell cycle was assessed in carcinoma cells. DNA synthesis was 
measured with EdU-PE incorporation and ploidy was assessed with FxCycle™ Far Red Stain in 
L2975 control and TOMM20 overexpressing cells after treatment with 0.5µM Palbociclib, 10µM 
Gemcitabine (Gemzar), and the combination of 0.5µM Palbociclib and 10µM Gemcitabine 
(Gemzar). E, Proliferation rates were measured with EdU incorporation and the cell cycle was 
assessed in carcinoma cells. DNA synthesis was measured with EdU-PE incorporation and 
Journal Pre-proof
ploidy was assessed with FxCycle™ Far Red Stainin L2975 control and TOMM20 
overexpressing cells after treatment with 1µM Palbociclib, 1µM Doxorubicin, and the 
combination of 1µM Palbociclib and 1µM Doxorubicin. F, Apoptosis levels were measured with 
Annexin-V (AnnV) and DAPI staining after treatment with 2µM Palbociclib, 10µM 
Gemcitabine, and the combination of 2µM Palbociclib and 10µM Gemcitabine. The percentage 
of apoptotic or dead L2975 cells (Annv-V- positive and/or DAPI positive) is shown. N= 3-4, 
*p<0.05 
 
Figure 5. Effect of TOMM20 overexpression on chondrosarcoma tumor growth.  A, Tumor volume 
and weight measurement at the time of collection of L2975 EV and TOMM20 after injection into the 
flank of athymic nude mice at time of collection. B, Tumor volume growth chart of tumor volume started 
when the tumors were initially detected to endpoint. C, Relative engraftment of L2975 EV and TOMM20 
tumors. D, Quantification of phospho-Rb staining measured by immunohistochemistry of the control and 
TOMM20 tumors and digitally quantified by Aperio software. E, Tumor volume and tumor weight 
measurement at the time of collection of CH2879 control and TOMM20 tumors injected into the flank of 
athymic nude mice. F, CH2879 tumor volume growth chart of tumor volume started when tumors were 
initially detected to endpoint. *p<0.05 
 
Figure 6. Expression of mitochondrial markers in murine tumors. A, Quantification of TOMM20 
protein levels normalized to β-actin control of tumors generated from EV control and TOMM20 
overexpression. B, Quantification of MCT1 protein levels normalized to β-actin of tumors generated from 
control and EV TOMM20 overexpression. C, Quantification of TIGAR protein levels normalized to β-
actin of tumors generated from EV control and TOMM20 overexpression. D, Quantification of 
mitoNEET protein levels normalized to β-actin of tumors generated from EV control and TOMM20 
overexpression. E, Quantification of BCL2 protein levels normalized to β-actin of tumors generated from 
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EV control and TOMM20 overexpression. F, Study schematic displaying the results of this study which 
include TOMM20 overexpression induces a more aggressive phenotype by increasing the expression of 
proteins involved in invasion and metastasis, proliferation, and resistance to apoptosis, promoting 




Table 1. Primary antibodies and their dilutions. 
Protein Company  Reference  Dilution 
N-Cadherin BD Biosciences BD-610820 1:1000 
Phosphorylated STAT3 
Tyrosine705 
Cell Signaling Technology  CST9145 1:1000 
c-MYC Cell Signaling Technology  CST5605 1:1000 
Cyclin D1 (DCS-6) Invitrogen MA5-12702 1:2000 
BCL2 Abcam ab181858 1:2000 
TIGAR Abcam ab31910 1:1000 
MCT1 Santa Cruz Biotechnology sc-365501 1:500 
MitoNEET (CDGSH iron sulfur 
domain 1) 




Table 2. Proteins that are upregulated with TOMM20 overexpression in chondrosarcoma. 
Protein name Abbreviation Pathway Fold Change 
CTRL vs. TOMM20  
Heat shock cognate 71kDa 
protein 
HSP7C Mitochondrial metabolism 1.5 
Elongation factor 1-delta EF1D Proliferation 1.6 
Calmodulin-2 CALM2 Proliferation 2.6 
Caldesmon CALD1 Proliferation 1.5 
Septin-11 SEP11 Proliferation 1.5 
Cysteine and glycine-rich 
protein 2 
CSRP2 Resistance to cell death 1.5 
Alpha-actinin-4 ACTN4 Dedifferentiation 1.9 
Myosin regulatory light chain 
12A 
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